The combination could represent an alternative for those who can’t tolerate high-intensity statin monotherapy.

Takeaway

• In patients with diabetes and atherosclerotic cardiovascular disease (ASCVD), ezetimibe combined with moderate-intensity statin therapy was comparable to high-intensity statin monotherapy in terms of cardiovascular event outcomes.
• The combination was associated with lower intolerance-related drug...